By Wendy Diller
Nearly two years ago, the FDA approved AstraZeneca PLC 's gefitinib (Iressa) and a year later ImClone Systems Inc....
Enthusiasm for biomarkers to guide drug development and clinical decision making is high, but given how little we know about them, biomarkers are a risky investment, as shown by experiences with EGFR inhibitors.
By Wendy Diller
Nearly two years ago, the FDA approved AstraZeneca PLC 's gefitinib (Iressa) and a year later ImClone Systems Inc....
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.